Matinas BioPharma Receives NYSE Notice of Listing Noncompliance

What Happened
Matinas BioPharma Holdings, Inc. (MTNB) announced that on August 31, 2026 it received a written notice from NYSE American saying the company is not in compliance with Section 1003(a)(i) of the NYSE American Company Guide. The noncompliance was based on reported stockholders’ equity of $1.8 million as of June 30, 2026, compared with the $2.0 million minimum required when a company has reported losses in recent years. The company issued a press release on September 4, 2026 regarding the notice.

Key Details

• NYSE notice date: August 31, 2026.
• Stockholders’ equity reported: $1.8 million as of June 30, 2026.
• NYSE Rule cited: Section 1003(a)(i) — requires ≥ $2.0 million equity if there are reported losses.
• Company reported losses from continuing operations and/or net losses in each of its five most recent fiscal years.
• Company issued a press release on September 4, 2026 to discuss the matter (included as an exhibit to the 8‑K).

Why It Matters
A formal NYSE notice of noncompliance signals the company does not meet a key listing standard; under exchange procedures this can lead to further review and, if not resolved, potential delisting. For investors, this raises possible risks to share liquidity and marketability and is a reason to monitor Matinas’ upcoming SEC filings and public statements for any remediation plan or timeline to regain compliance.